- Home
- MVST vs BWAY Comparison
MVST vs BWAY Comparison
Compare MVST & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- BWAY
- Stock Information
- Founded
- MVST 2006
- BWAY 2003
- Country
- MVST United States
- BWAY Israel
- Employees
- MVST N/A
- BWAY N/A
- Industry
- MVST Industrial Machinery/Components
- BWAY Medical/Dental Instruments
- Sector
- MVST Miscellaneous
- BWAY Health Care
- Exchange
- MVST Nasdaq
- BWAY Nasdaq
- Market Cap
- MVST 848.0M
- BWAY 280.7M
- IPO Year
- MVST N/A
- BWAY 2019
- Fundamental
- Price
- MVST $3.44
- BWAY $15.96
- Analyst Decision
- MVST Strong Buy
- BWAY Strong Buy
- Analyst Count
- MVST 1
- BWAY 2
- Target Price
- MVST $6.00
- BWAY $18.00
- AVG Volume (30 Days)
- MVST 4.8M
- BWAY 78.1K
- Earning Date
- MVST 11-11-2025
- BWAY 11-11-2025
- Dividend Yield
- MVST N/A
- BWAY N/A
- EPS Growth
- MVST N/A
- BWAY 515.14
- EPS
- MVST N/A
- BWAY 0.11
- Revenue
- MVST $422,605,000.00
- BWAY $46,084,000.00
- Revenue This Year
- MVST $24.21
- BWAY $335.63
- Revenue Next Year
- MVST $31.67
- BWAY $22.10
- P/E Ratio
- MVST N/A
- BWAY $57.26
- Revenue Growth
- MVST 20.84
- BWAY 26.50
- 52 Week Low
- MVST $0.15
- BWAY $7.84
- 52 Week High
- MVST $4.72
- BWAY $17.00
- Technical
- Relative Strength Index (RSI)
- MVST 66.29
- BWAY 58.98
- Support Level
- MVST $3.18
- BWAY $15.74
- Resistance Level
- MVST $3.45
- BWAY $17.00
- Average True Range (ATR)
- MVST 0.19
- BWAY 0.65
- MACD
- MVST 0.10
- BWAY -0.08
- Stochastic Oscillator
- MVST 93.03
- BWAY 56.30
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.